搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
FierceBiotech
49 分钟
Genfit moves to jump-start enrollment in slow-going phase 2 liver failure trial
Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...
FierceBiotech
2 小时
Chutes & Ladders—2 Kite vets fly over to Kyverna Therapeutics
Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...
FierceBiotech
3 小时
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
FierceBiotech
6 小时
Edgewise's stock jumps 50% on the back of safety data for potential heart disease rival to ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
FierceBiotech
22 小时
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...
FierceBiotech
23 小时
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
William McEwan, Ph.D., spent years unraveling how an antiviral protein, tripartite motif-containing 21 (TRIM21), protects our ...
FierceBiotech
1 天
Achilles drops cell therapy program, braces for layoffs after missing 'commercial viability ...
Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...
FierceBiotech
1 天
Aligos' MASH prospect slashes liver fat in phase 2, but stock drops anyway
Aligos Therapeutics is heralding a midstage win in metabolic-dysfunction associated steatohepatitis (MASH) after three ...
FierceBiotech
1 天
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...
FierceBiotech
1 天
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell ...
GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...
FierceBiotech
1 天
Inflammation-focused Upstream set to join growing trickle of biotech IPOs
The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...
FierceBiotech
1 天
NIH grants up to $100M yearly for pandemic preparedness network
With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈